Learn more about new FDA recommendations on oral fluoride supplements and what doctors recommend for oral care in young ...

The latest move is set to cut costs of starting oral doses of GLP-1s to as low as around $150 for certain groups of people ...

Since the start of this year, Sudan has recorded 71,373 cholera cases and 1,996 deaths, marking the highest number of fatalities from cholera in Africa during the period, Yap Boum II, deputy incident ...

“Certainly, diabetes and hypertension raise the risk of heart disease,” Dr. Graham said. But autoimmune conditions may also ...

Looking for a natural way to lower your blood pressure? Experts say this everyday drink can help improve heart health ...

Figures show flu cases are already more than three times higher than the same point last year, largely driven by a surge ...

Certain GLP-1 weight loss medications will be available for as little as $149 per month, a sharp drop from the current ...

Here, cardiologists share the heart disease risk factors that influence your likelihood developing heart disease, from things ...

Vought has exerted extraordinary control over government spending this year, usurping congressional decisions on how the nation’s money is used.

Novo Nordisk A/S & Eli Lilly and Company cut prices for top diabetes drugs, boosting accessibility and potential revenue.

Recent Gallup data shows a decline in U.S. obesity rates, likely linked to widespread use of GLP-1 drugs like Ozempic and Wegovy.

Late-breaking presentation of Explore-CKD trial at ASN Kidney Week – – Pivotal Phase 3 Launch-HTN trial featured in the “Best of JAMA and NEJM” session - RADNOR, Pa., ...